4-([(9H-Fluoren-9-ylmethoxy)carbonyl]amino)pentanoic acid | 1343035-80-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 芴
• 英文名称: 4-([(9H-Fluoren-9-ylmethoxy)carbonyl]amino)pentanoic acid
• 英文别名: 4-(9H-fluoren-9-ylmethoxycarbonylamino)pentanoic acid
• CAS: 1343035-80-2
• 化学式: C₂₀H₂₁NO₄
• 分子量: 339.4
• InChiKey: ASUWOMDZJCFFDR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  25
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  75.6
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• [EN] HETEROCYCLIC COMPOUNDS AS HIV PROTEASE INHIBITORS<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES EN TANT QU'INHIBITEURS DE LA PROTÉASE DU VIH
  申请人：MERCK SHARP & DOHME

  公开号：WO2018106519A1

  公开（公告）日：2018-06-14

  The present invention is directed to compounds of Formula (I), pharmaceutical compositions comprising the same, and their use in the inhibition of HIV protease, the inhibition of HIV replication, the prophylaxis of infection by HIV, the treatment of infection by HIV, and the prophylaxis, treatment, and delay in the onset or progression of AIDS.

  本发明涉及式(I)的化合物，包括相同的药物组合物，以及它们在抑制HIV蛋白酶、抑制HIV复制、预防HIV感染、治疗HIV感染以及预防、治疗和延缓艾滋病的发病或进展中的用途。
• ANGIOTENSIN II RECEPTOR BLOCKER DERIVATIVES
  申请人：Almirante Nicoletta

  公开号：US20110052674A1

  公开（公告）日：2011-03-03

  New angiotensin II receptor blocker nitroderivatives of general formula (I) and pharmaceutically acceptable salts or stereoisomers thereof: and their use for treating cardiovascular, renal and chronic liver diseases, inflammatory processes and metabolic syndromes.

  新的血管紧张素II受体拮抗剂，通式为(I)和其药学上可接受的盐或立体异构体：以及它们用于治疗心血管，肾脏和慢性肝脏疾病，炎症过程和代谢综合征。
• INHIBITORS OF STAT3 AND USES THEREOF
  申请人：McMurray John S.

  公开号：US20120035114A1

  公开（公告）日：2012-02-09

  Compounds which inhibit the activity of signal transducer and activator of transcription 3 (STAT3) are provided together with methods of making and using the same. The compounds are designed to bind to the SH2 domain of STAT3, preventing STAT3 from binding to receptors for interleukin-6 family cytokines, growth factors such as the platelet-derived growth factor, the epidermal growth factor, vascular endothelial growth factor, and other signaling molecules such as leptin. Blocking these interactions prevents STAT3 from being phosphorylated on Tyr705, which is required for the dimerization of STAT3, translocation to the nucleus, binding to STAT3 response elements on promotors, and transcription of genes. In addition to these activities, binding to the SH2 domain of STAT3 breaks up pre-formed dimmers, thereby preventing the transcriptional activity of the inhibitor.

  本发明提供了抑制信号转导与激活转录因子3 (STAT3) 活性的化合物，以及制备和使用这些化合物的方法。这些化合物被设计成结合STAT3的SH2结构域，防止STAT3与白细胞介素6家族细胞因子、血小板源性生长因子、表皮生长因子、血管内皮生长因子等生长因子和瘦素等信号分子的受体结合。阻断这些相互作用可防止STAT3在Tyr705位点磷酸化，这是STAT3二聚化、向细胞核转位、结合启动子上的STAT3响应元件和基因转录所必需的。除了这些作用，结合STAT3的SH2结构域还可以分解已形成的二聚体，从而防止抑制剂的转录活性。
• Heterocyclic compounds as HIV protease inhibitors
  申请人：Merck Sharp & Dohme Corp.

  公开号：US10696639B2

  公开（公告）日：2020-06-30

  The present invention is directed to compounds of Formula (I), pharmaceutical compositions comprising the same, and their use in the inhibition of HIV protease, the inhibition of HIV replication, the prophylaxis of infection by HIV, the treatment of infection by HIV, and the prophylaxis, treatment, and delay in the onset or progression of AIDS.

  本发明涉及式(I)化合物、包含式(I)化合物的药物组合物及其在抑制艾滋病毒蛋白酶、抑制艾滋病毒复制、预防艾滋病毒感染、治疗艾滋病毒感染以及预防、治疗和延缓艾滋病的发生或发展中的用途。
• HETEROCYCLIC COMPOUNDS AS HIV PROTEASE INHIBITORS
  申请人：Merck Sharp & Dohme Corp.

  公开号：EP3551192A1

  公开（公告）日：2019-10-16